Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Stemmer SM, Steiner M, Rizel S, Ben-Baruch N, Uziely B, Jakubowski DM, Baron J, Shak S, Soussan-Gutman L, Bareket-Samish A, Fried G, Rosengarten O, Itay A, Nisenbaum B, Katz D, Leviov M, Tokar M, Liebermann N, Geffen DB.
Stemmer SM, et al. Among authors: shak s.
NPJ Breast Cancer. 2019 Nov 8;5:41. doi: 10.1038/s41523-019-0137-3. eCollection 2019.
NPJ Breast Cancer. 2019.
PMID: 31728408
Free PMC article.
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided by the RS result are l …
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen recepto …